← Rolf Wachter

Papers by Rolf Wachter

Page 3 · newest first

101. Baseline Characteristics of Patients in the PARALLAX Trial: Insights Into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure · 2021
102. Expert opinion paper on cardiac imaging after ischemic strokeClinical Research in Cardiology · 2021
103. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic riskfactors in HFpEF patients2021
104. Extra-Cardiac Targets in the Management of Cardiometabolic Disease: Device-Based TherapiesENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2021
105. Hospitalizations for Heart Failure: Still Major Differences Between East and West Germany 30 Years After ReunificationESC Heart Failure · 2021
106. Screening for Atrial Fibrillation in the Older PopulationJAMA Cardiology · 2021
107. The Diagnostic and Prognostic Value of Galectin-3 in Patients at Risk for Heart Failure with Preserved Ejection Fraction: Results from the DIAST-CHF StudyESC Heart Failure · 2021
108. Prognostic value of right atrial dilation in patients with pulmonary embolismERJ Open Research · 2021
109. Quality of Life 3 and 12 Months Following Acute Pulmonary EmbolismCHEST Journal · 2021
110. Exercise Stress Real-Time Cardiac Magnetic Resonance Imaging for Noninvasive Characterization of Heart Failure With Preserved Ejection FractionCirculation · 2021
111. Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial FibrillationCardiology · 2021
112. Heart Failure is Independently Associated with White Matter Lesions: Insights from the Population-Based LIFE-Adult StudyESC Heart Failure · 2020
113. Efficacy of team-based collaborative care for distressed patients in secondary prevention of chronic coronary heart disease (TEACH): study protocol of a multicenter randomized controlled trialBMC Cardiovascular Disorders · 2020
114. Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillationClinical Research in Cardiology · 2020
115. Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failureBioPsychoSocial Medicine · 2020
116. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation RegistryInternal and Emergency Medicine · 2020
117. Software‐based analysis of 1‐hour Holter ECG to select for prolonged ECG monitoring after strokeAnnals of Clinical and Translational Neurology · 2020
118. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection FractionJACC Heart Failure · 2020
119. Heart Failure Signs and Symptoms, Hospital Referrals, and Prescription Patterns in Patients Receiving Sacubitril/Valsartan in Primary Care and Cardiologist Settings in GermanyESC Heart Failure · 2020
120. The Impact of Pharmacist/Physician Care on Quality of Life in Elderly Heart Failure Patients: Results of the PHARM-CHF Randomized Controlled TrialESC Heart Failure · 2020
121. Heart Failure Patients with Atrial Fibrillation Benefit from Remote Patient Management: Insights from the TIM-HF2 TrialESC Heart Failure · 2020
122. Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trialsEuropean Journal of Heart Failure · 2020
123. Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fractionIJC Heart & Vasculature · 2020
124. Angiotensin Receptor Neprilysin Inhibition versus Individualized RAAS Blockade: Design and Rationale of the PARALLAX TrialESC Heart Failure · 2020
125. Syncopes and Clinical Outcome in Heart Failure: Results from Prospective Clinical Study Data in GermanyESC Heart Failure · 2020
126. Economic Impact of Heart Failure with Preserved Ejection Fraction: Insights from the ALDO-DHF TrialESC Heart Failure · 2020
127. Initiation of Sacubitril/Valsartan Shortly After Hospitalisation for Acutely Decompensated Heart Failure in Patients with Newly Diagnosed ( de novo ) Heart Failure: A Subgroup Analysis of the TRANSITION StudyEuropean Journal of Heart Failure · 2019
128. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After StrokeStroke · 2019
129. Searching for Atrial Fibrillation PoststrokeCirculation · 2019
130. Atrial fibrillation is frequent but does not affect risk stratification in pulmonary embolismJournal of Internal Medicine · 2019
131. 1410Clinical predictors of NT-proBNP response to early initiation of sacubitril/valsartan after hospitalisation for decompensated heart failure: An analysis of the TRANSITION studyEuropean Heart Journal · 2019
132. Blended collaborative care in the secondary prevention of coronary heart disease improves risk factor control: Results of a randomised feasibility studyEuropean Journal of Cardiovascular Nursing · 2019
133. NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic StrokeStroke · 2019
134. Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patientsCurrent Medical Research and Opinion · 2019
135. Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral IschemiaStroke · 2019
136. Initiation of Sacubitril/Valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early After Discharge: Primary Results of the Randomised TRANSITION StudyEuropean Journal of Heart Failure · 2019
137. The cardiac diagnostic work-up in stroke patients—A subanalysis of the Find-AFRANDOMISED trialPLoS ONE · 2019
138. Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection FractionJournal of Clinical Medicine · 2019
139. Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in GermanyEuropean Journal of Heart Failure · 2019
140. Motivational Interviewing Can Support Physical Activity in Elderly Patients with Diastolic Heart Failure: Results from a Pilot StudyESC Heart Failure · 2019
141. Vitamin D Deficiency in Patients with Diastolic Dysfunction or Heart Failure with Preserved Ejection FractionESC Heart Failure · 2019
142. Development and validation of a score to detect paroxysmal atrial fibrillation after strokeNeurology · 2018
143. Kidney protective effects of baroreflex activation therapy in patients with resistant hypertensionJournal of Clinical Hypertension · 2018
144. P886Initiation of sacubitril/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: primary results of the TRANSITION studyEuropean Heart Journal · 2018
145. Rationale and Design of a Multicentre, Randomized, Placebo-Controlled Trial of Mirabegron, a Beta3-Adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients with Structural Heart Disease Beta3-Left Ventricular Hypertrophy (Beta3-LVH)ESC Heart Failure · 2018
146. Cross-Sectional and Longitudinal Associations of Systolic Blood Pressure With Quality of Life and Depressive Mood in Older Adults With Cardiovascular Risk Factors: Results From the Observational DIAST-CHF StudyPsychosomatic Medicine · 2018
147. Biomarker-Based Phenotyping of Myocardial Fibrosis Identifies Patients with Heart Failure with Preserved Ejection Fraction Resistant to the Beneficial Effects of Spironolactone: Results From the Aldo-DHF TrialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2018
148. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertensionJournal of Hypertension · 2018
149. Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fractionBiomarkers · 2018
150. Prognostic impact of copeptin in pulmonary embolism: a multicentre validation studyEuropean Respiratory Journal · 2018